Capricor Therapeutics, Inc. (CAPR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 465.69M USD. 52-week range 2.96 to 40.37 USD. Data as of 2026-10-09.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial ...